The facility consists of a $33.1 million term loan, a $3.0 million equipment term loan and a $3.0 million revolving credit facility (collectively, the “Loans”), all of which mature in 2022.
Read More
Successful in building a diverse and robust cultivation pipeline, have made progress on adding value through the research and development of derivative cannabis products.
Read More
Novus is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).
Read More
The combined proceeds, approximately $120 to 140 million on an after-tax basis, will immediately be applied to reduce the Company’s indebtedness.
Read More
GW was awarded the voucher under a U.S. Food and Drug Administration (FDA) program intended to...
Read More
Total gross revenue for the quarter reached $16.2 million, an increase of 144% from the previous...
Read More
CV Sciences, Inc. finished 2018 with strong sales momentum and enters 2019 well positioned to...
Read More
Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing...
Read More
The Company is currently in the final stages of talks with a leading Ontario based...
Read More
Get stock alerts, news & related alerts straight to your inbox!